Skip to content

Orticumab featured in Cardiovascular Business post on AI and inflammation. Read the Article.

Abcentra logo
  • Our Company
  • Coronary Artery Disease
  • Orticumab
  • Resources
  • Our Company
  • Coronary Artery Disease
  • Orticumab
  • Resources
  • Contact Us
Contact Us
Previous Next
  • View Larger Image International Atherosclerosis Society Logo on grey background

Inhibition of injury-induced arterial remodeling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100

By Ben Huizinga|2024-03-12T18:54:53+00:00March 12, 2024|

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: Ben Huizinga

Keep up to date on Abcentra’s work

Get press releases and other timely announcements directly to your email inbox.

Thank you for subscribing! We look forward to connecting soon.
There was an error trying to send your message. Please try again later.
Abcentra white logo

© 2024 Abcentra LLC • All Rights Reserved • Terms of Use • Privacy Policy
Abcentra's pharmaceutical products are investigational and not FDA approved.

Page load link
Go to Top